Merck & Co., Inc. (MRK) stock
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30220% above fair value
$133.72+0.91 (+0.69%)
Close on Nov 20, 2026Market cap $329.91BP/E 107.0Yield 2.45%
Merck free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Merck's free cash flow for the twelve months ending Jun 30, 2026 was $16.06B, up 9.1% year over year. For fiscal 2025 it was $12.36B, down 31.7% from the year before. Over ten years it grew 0.9% a year on average. The highest annual figure on record is $18.10B in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.36B | -31.7% |
| FY2024 | Dec 31, 2024 | $18.10B | +97.9% |
| FY2023 | Dec 31, 2023 | $9.14B | -37.8% |
| FY2022 | Dec 31, 2022 | $14.71B | +69.6% |
| FY2021 | Dec 31, 2021 | $8.67B | +172.1% |
| FY2020 | Dec 31, 2020 | $3.19B | -42.2% |
| FY2019 | Dec 31, 2019 | $5.52B | -33.6% |
| FY2018 | Dec 31, 2018 | $8.31B | +82.1% |
| FY2017 | Dec 31, 2017 | $4.56B | -47.9% |
| FY2016 | Dec 31, 2016 | $8.76B | -22.2% |
| FY2015 | Dec 31, 2015 | $11.26B | +68.7% |
| FY2014 | Dec 31, 2014 | $6.67B | -34.0% |
| FY2013 | Dec 31, 2013 | $10.11B | +25.3% |
| FY2012 | Dec 31, 2012 | $8.07B | -24.3% |
| FY2011 | Dec 31, 2011 | $10.66B | +16.6% |
| FY2010 | Dec 31, 2010 | $9.14B | +373.5% |
| FY2009 | Dec 31, 2009 | $1.93B | -63.4% |
| FY2008 | Dec 31, 2008 | $5.27B | -11.9% |
| FY2007 | Dec 31, 2007 | $5.99B | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.48B | +77.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.93B | +149.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.82B | -27.4% |
| Q3 FY2025 | Sep 30, 2025 | $6.84B | -19.7% |
| Q2 FY2025 | Jun 30, 2025 | $2.53B | -47.8% |
| Q1 FY2025 | Mar 31, 2025 | $1.17B | -47.4% |
| Q4 FY2024 | Dec 31, 2024 | $2.51B | – |
| Q3 FY2024 | Sep 30, 2024 | $8.51B | +24.8% |
| Q2 FY2024 | Jun 30, 2024 | $4.85B | +76.9% |
| Q1 FY2024 | Mar 31, 2024 | $2.23B | +571.4% |
| Q4 FY2023 | Dec 31, 2023 | -$743.00M | -122.6% |
| Q3 FY2023 | Sep 30, 2023 | $6.82B | +52.3% |
| Q2 FY2023 | Jun 30, 2023 | $2.74B | -13.7% |
| Q1 FY2023 | Mar 31, 2023 | $332.00M | -91.2% |
| Q4 FY2022 | Dec 31, 2022 | $3.28B | -15.6% |
| Q3 FY2022 | Sep 30, 2022 | $4.48B | +23.5% |
| Q2 FY2022 | Jun 30, 2022 | $3.17B | +216.0% |
| Q1 FY2022 | Mar 31, 2022 | $3.78B | +2290.5% |
| Q4 FY2021 | Dec 31, 2021 | $3.89B | +96.4% |
| Q3 FY2021 | Sep 30, 2021 | $3.63B | +2546.0% |
| Q2 FY2021 | Jun 30, 2021 | $1.00B | -25.7% |
| Q1 FY2021 | Mar 31, 2021 | $158.00M | – |
| Q4 FY2020 | Dec 31, 2020 | $1.98B | – |
| Q3 FY2020 | Sep 30, 2020 | $137.00M | -95.8% |
| Q2 FY2020 | Jun 30, 2020 | $1.35B | -41.3% |
| Q1 FY2020 | Mar 31, 2020 | -$279.00M | -137.7% |
| Q4 FY2019 | Dec 31, 2019 | -$795.00M | -129.9% |
| Q3 FY2019 | Sep 30, 2019 | $3.27B | +52.7% |
| Q2 FY2019 | Jun 30, 2019 | $2.30B | -17.8% |
| Q1 FY2019 | Mar 31, 2019 | $741.00M | +5.1% |
| Q4 FY2018 | Dec 31, 2018 | $2.66B | -19.4% |
| Q3 FY2018 | Sep 30, 2018 | $2.14B | – |
| Q2 FY2018 | Jun 30, 2018 | $2.80B | -4.3% |
| Q1 FY2018 | Mar 31, 2018 | $705.00M | – |
| Q4 FY2017 | Dec 31, 2017 | $3.30B | +7.2% |
| Q3 FY2017 | Sep 30, 2017 | -$1.61B | -162.9% |
| Q2 FY2017 | Jun 30, 2017 | $2.92B | – |
| Q1 FY2017 | Mar 31, 2017 | -$53.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.08B | – |
| Q3 FY2016 | Sep 30, 2016 | $2.56B | – |
See a number that looks wrong?